Last updated on January 2019

An Open-Label Phase 2 Study in Participants with Primary Sjogren's Syndrome

Brief description of study

Primary Outcome Measures:

  • Proportion of participants with a 1 point or greater change on the salivary gland ultrasound (SGUS) score for parotid and submandibular glands [ Time Frame: Week 4 and Week 12 ]
  • To determine the impact of INCB050465 on salivary gland echostructure.

Secondary Outcome Measures:

  • Change from baseline in salivary CXCL13 levels [ Time Frame: Baseline, Week 4 and Week 12 ]
  • To assess the impact of INCB050465 on salivary CXCL13.


Number of treatment-emergent adverse events [ Time Frame: Up to 21 weeks ]

Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.



Clinical Study Identifier: TX217911

Find a site near you

Start Over

Advanced Pharma - Miami

2950 NW 83rd Street Miami, FL United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.